Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Heather L. Howie is active.

Publication


Featured researches published by Heather L. Howie.


Haematologica | 2016

Metabolic pathways that correlate with post-transfusion circulation of stored murine red blood cells.

Karen de Wolski; Xiaoyoun Fu; Larry J. Dumont; John D. Roback; Hayley R. Waterman; Katherine Odem-Davis; Heather L. Howie; James C. Zimring

Transfusion of red blood cells is a very common inpatient procedure, with more than 1 in 70 people in the USA receiving a red blood cell transfusion annually. However, stored red blood cells are a non-uniform product, based upon donor-to-donor variation in red blood cell storage biology. While thousands of biological parameters change in red blood cells over storage, it has remained unclear which changes correlate with function of the red blood cells, as opposed to being co-incidental changes. In the current report, a murine model of red blood cell storage/transfusion is applied across 13 genetically distinct mouse strains and combined with high resolution metabolomics to identify metabolic changes that correlated with red blood cell circulation post storage. Oxidation in general, and peroxidation of lipids in particular, emerged as changes that correlated with extreme statistical significance, including generation of dicarboxylic acids and monohydroxy fatty acids. In addition, differences in anti-oxidant pathways known to regulate oxidative stress on lipid membranes were identified. Finally, metabolites were identified that differed at the time the blood was harvested, and predict how the red blood cells perform after storage, allowing the potential to screen donors at time of collection. Together, these findings map out a new landscape in understanding metabolic changes during red blood cell storage as they relate to red blood cell circulation.


PLOS Pathogens | 2015

β-HPV 5 and 8 E6 disrupt homology dependent double strand break repair by attenuating BRCA1 and BRCA2 expression and foci formation.

Nicholas A. Wallace; Kristin Robinson; Heather L. Howie; Denise A. Galloway

Recent work has explored a putative role for the E6 protein from some β-human papillomavirus genus (β-HPVs) in the development of non-melanoma skin cancers, specifically β-HPV 5 and 8 E6. Because these viruses are not required for tumor maintenance, they are hypothesized to act as co-factors that enhance the mutagenic capacity of UV-exposure by disrupting the repair of the resulting DNA damage. Supporting this proposal, we have previously demonstrated that UV damage signaling is hindered by β-HPV 5 and 8 E6 resulting in an increase in both thymine dimers and UV-induced double strand breaks (DSBs). Here we show that β-HPV 5 and 8 E6 further disrupt the repair of these DSBs and provide a mechanism for this attenuation. By binding and destabilizing a histone acetyltransferase, p300, β-HPV 5 and 8 E6 reduce the enrichment of the transcription factor at the promoter of two genes critical to the homology dependent repair of DSBs (BRCA1 and BRCA2). The resulting diminished BRCA1/2 transcription not only leads to lower protein levels but also curtails the ability of these proteins to form repair foci at DSBs. Using a GFP-based reporter, we confirm that this reduced foci formation leads to significantly diminished homology dependent repair of DSBs. By deleting the p300 binding domain of β-HPV 8 E6, we demonstrate that the loss of robust repair is dependent on viral-mediated degradation of p300 and confirm this observation using a combination of p300 mutants that are β-HPV 8 E6 destabilization resistant and p300 knock-out cells. In conclusion, this work establishes an expanded ability of β-HPV 5 and 8 E6 to attenuate UV damage repair, thus adding further support to the hypothesis that β-HPV infections play a role in skin cancer development by increasing the oncogenic potential of UV exposure.


mAbs | 2017

Affinity of human IgG subclasses to mouse Fc gamma receptors

Gillian Dekkers; Arthur E. H. Bentlage; Tamara C. Stegmann; Heather L. Howie; Suzanne N. Lissenberg-Thunnissen; James C. Zimring; Theo Rispens; Gestur Vidarsson

ABSTRACT Human IgG is the main antibody class used in antibody therapies because of its efficacy and longer half-life, which are completely or partly due to FcγR-mediated functions of the molecules. Preclinical testing in mouse models are frequently performed using human IgG, but no detailed information on binding of human IgG to mouse FcγRs is available. The orthologous mouse and human FcγRs share roughly 60–70% identity, suggesting some incompatibility. Here, we report binding affinities of all mouse and human IgG subclasses to mouse FcγR. Human IgGs bound to mouse FcγR with remarkably similar binding strengths as we know from binding to human ortholog receptors, with relative affinities IgG3>IgG1>IgG4>IgG2 and FcγRI>>FcγRIV>FcγRIII>FcγRIIb. This suggests human IgG subclasses to have similar relative FcγR-mediated biological activities in mice.


Transfusion | 2016

Serological blind spots for variants of human IgG3 and IgG4 by a commonly used anti-immunoglobulin reagent.

Heather L. Howie; Meghan Delaney; Xiaohong Wang; Lay See Er; Gestur Vidarsson; Tamara C. Stegmann; Linda M. Kapp; Jenna N. Lebedev; Yanyun Wu; James P. AuBuchon; James C. Zimring

Human immunoglobulin G (IgG) includes four different subtypes (IgG1, IgG2, IgG3, and IgG4), and it is also now appreciated that there are genetic variations within IgG subtypes (called isoallotypes). Twenty‐nine different isoallotypes have been described, with 7, 4, 15, and 3 isoallotypes described for IgG1, IgG2, IgG3, and IgG4, respectively. The reactivity of anti‐IgG with different isoallotypes has not been characterized.


JCI insight | 2017

Errors in data interpretation from genetic variation of human analytes

Heather L. Howie; Meghan Delaney; Xiaohong Wang; Lay See Er; Linda M. Kapp; Jenna N. Lebedev; James C. Zimring

In recent years, the extent of our vulnerability to misinterpretation due to poorly characterized reagents has become an issue of great concern. Antibody reagents have been identified as a major source of error, contributing to the reproducibility crisis. In the current report, we define an additional dimension of the crisis; in particular, we define variation of the targets being analyzed. We report that natural variation in the immunoglobulin constant region alters the reactivity with commonly used subtype-specific anti-IgG reagents, resulting in cross-reactivity of polyclonal regents with inappropriate targets and blind spots of monoclonal reagents for desired targets. This raises the practical concern that numerous studies characterizing IgG subtypes in human disease may contain errors due to such previously unappreciated defects. These studies also focus attention on the broader concern that genetic variation may affect the performance of any laboratory or research test that uses antibodies for detection.


Frontiers in Immunology | 2016

regulatory T cells are Dispensable for Tolerance to rBc antigens

Amanda L. Richards; Linda M. Kapp; Xiaohong Wang; Heather L. Howie; Krystalyn E. Hudson

Autoimmune hemolytic anemia (AIHA) occurs when pathogenic autoantibodies against red blood cell (RBC) antigens are generated. While the basic disease pathology of AIHA is well studied, the underlying mechanism(s) behind the failure in tolerance to RBC autoantigens are poorly understood. Thus, to investigate the tolerance mechanisms required for the establishment and maintenance of tolerance to RBC antigens, we developed a novel murine model. With this model, we evaluated the role of regulatory T cells (Tregs) in tolerance to RBC-specific antigens. Herein, we show that neither sustained depletion of Tregs nor immunization with RBC-specific proteins in conjunction with Treg depletion led to RBC-specific autoantibody generation. Thus, these studies demonstrate that Tregs are not required to prevent autoantibodies to RBCs and suggest that other tolerance mechanisms are likely involved.


Journal of Immunological Methods | 2018

Common murine immunoglobulin detection reagents have diminished reactivity with IgG3 – A vulnerability to misinterpretation

Heather L. Howie; Xiaohong Wang; Linda M. Kapp; Jenna N. Lebedev; Krystalyn E. Hudson; James C. Zimring

Methods designed to monitor humoral immune responses, in a variety of settings, typically use a broadly reactive detection reagent (e.g. polyclonal anti-Ig (immunoglobulin)) in order to characterize antibody responses. In the context of murine models of immunity, which are widely used, this would typically be antisera to mouse Ig or mouse IgG. However, there are 4 different subtypes of mouse IgG; thus, the validity of the above approach, as a general screen for humoral immune responses, depends upon the assumption that the antisera recognize all IgG subtypes. This seems like a reasonable assumption, since polyclonal antisera recognize multiple epitopes; however, herein we report that two commercial sources of goat anti-mouse Ig are hyporeactive with IgG3. Given that relative IgG3 levels are different in distinct types of immune response, these findings demonstrate a potential for misinterpretation, and suggest a need to modify immunological methods in this context.


Journal of Clinical Pathology | 2018

Identification of IgG3-specific epitope that remedies problem in diagnostic IgG subclass determination due to human genetic variation

Heather L. Howie; Xiaohong Wang; Linda M. Kapp; Jenna N. Lebedev; James C. Zimring

There are four subtypes of human IgG with different effector functions. Quantifying the relative amount of each IgG subtype is important for laboratory diagnosis in multiple settings. However, in an evolving landscape of the appreciation of human variability and the need for precision/personalised laboratory diagnosis, it has also been shown that there are numerous natural variants of IgG subtypes, with at least 29 having been described. It has recently been reported that commercially available polyclonal antisera to IgG3 cross react with variants of other IgG subtypes, while available monoclonal anti-IgG3 have a blind-spot for the IgG3-04 variant. Herein, we report that IgG3-04 contains an epitope in common with all known IgG3 variants and absent in other subtypes. A novel monoclonal anti-IgG3 is described that is specific to IgG3 but without any blind-spots for known IgG3 variants, providing a remedy to the problem of genetic variability of IgG3.


Frontiers in Immunology | 2017

Innate B-1 B Cells Are Not Enriched in Red Blood Cell Autoimmune Mice: Importance of B Cell Receptor Transgenic Selection

Amanda L. Richards; Heather L. Howie; Linda M. Kapp; Jeanne E. Hendrickson; James C. Zimring; Krystalyn E. Hudson

Autoimmune hemolytic anemia (AIHA) results from breakdown of humoral tolerance to RBC antigens. Past analyses of B-cell receptor transgenic (BCR-Tg) mice that recognize RBC autoantigens led to a paradigm in which autoreactive conventional B-2 B cells are deleted whereas extramedullary B-1 B cells escape deletion due to lack of exposure to RBCs. However, BCR-Tg mice utilized to shape the current paradigm were unable to undergo receptor editing or class-switching. Given the importance of receptor editing as mechanism to tolerize autoreactive B cells during central tolerance, we hypothesized that expansion of autoreactive B-1 B cells is a consequence of the inability of the autoreactive BCR to receptor edit. To test this hypothesis, we crossed two separate strains of BCR-Tg mice with transgenic mice expressing the BCR target on RBCs. Both BCR-Tg mice express the same immunoglobulin and, thus, secrete antibodies with identical specificity, but one strain (SwHEL) has normal receptor editing, whereas the other (IgHEL) does not. Similar to other AIHA models, the autoreactive IgHEL strain showed decreased B-2 B cells, an enrichment of B-1 B cells, and detectable anti-RBC autoantibodies and decreased RBC hematocrit and hemoglobin values. However, autoreactive SwHEL mice had induction of tolerance in both B-2 and B-1 B cells with anti-RBC autoantibody production without anemia. These data generate new understanding and challenge the existing paradigm of B cell tolerance to RBC autoantigens. Furthermore, these findings demonstrate that immune responses vary when BCR-Tg do not retain BCR editing and class-switching functions.


Human Immunology | 2016

P058 Validation of anti-human antibodies used in flow cytometric crossmatching

Paul Warner; Linda M. Kapp; Heather L. Howie; James C. Zimring

Aim Flow cytometric crossmatches (FCXM) are widely used to detect recipient alloantibodies against donor tissue to assess compatibility for transplantation. Polyclonal anti-human globulin (AHG) is the reagent typically utilized for the detection of these alloantibodies. Humans produce four primary subtypes of IgG, designated as IgG1–4. Here, we describe a system to determine whether the AHG is able to detect all IgG subtypes. Methods Humanized monoclonal antibodies of each IgG subtype, specific for a red blood cell (RBC) antigen were produced. Briefly, the cDNA for the complimentarity-determining regions (CDR) of the heavy and light chains specific for the Kell RBC antigen were ligated into expression vectors for the separate IgG subtypes 1–4 and kappa light chains, co-transfected into CHO cells, and purified. These monoclonal IgG1–4 antibodies were then tested against RBCs, and three different lots of AHG were used to detect the antibodies bound to the RBCs in a standard FCXM assay. An anti-kappa light chain antibody that recognizes an epitope common in all IgG subtypes was used as a positive control. The AHG alone was used as a baseline control. Results As shown in Fig. 1, each lot of AHG was able to detect all four subtypes of IgG. In addition, titration experiments were performed to determine whether there was preferential detection of any IgG subtype(s). These experiments demonstrated that AHG does exhibit preferential binding to different IgG subtypes. In one specific lot of AHG, the hierarchy of binding/detection was IgG3xa0>xa0IgG1xa0>xa0IgG2xa0>xa0IgG4. Download : Download high-res image (264KB) Download : Download full-size image Conclusion These data provide a proof-of-principle for a method to characterize and validate AHG reagents used in FCXM assays. This is important, because the inability of AHG reagents to detect IgG subtypes may lead to false-negative FCXM results. These animal-derived AHG reagents are polyclonal, and there may be lot-to-lot variability in their ability to detect different IgG subtypes. J. Zimring:xa0Grant/Research Support; Company/Organization; Immucor, Inc.. Scientific/Medical Advisor; Company/Organization; Rubius Therapeutics. Employee; Company/Organization; Bloodworks NW.

Collaboration


Dive into the Heather L. Howie's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Meghan Delaney

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Adam D. Munday

Puget Sound Blood Center

View shared research outputs
Top Co-Authors

Avatar

Ariel Hay

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Denise A. Galloway

Fred Hutchinson Cancer Research Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge